Cargando…
Use of pharmacogenomics in pediatric renal transplant recipients
Transplant recipients receive potent immunosuppressive drugs in order to prevent graft rejection. Therapeutic drug monitoring is the current approach to guide the dosing of calcineurin inhibitors, mammalian target of rapamycin inhibitors (mTORi) and mofetil mycophenolate. Target concentrations used...
Autores principales: | Medeiros, Mara, Castañeda-Hernández, Gilberto, Ross, Colin J. D., Carleton, Bruce C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332348/ https://www.ncbi.nlm.nih.gov/pubmed/25741362 http://dx.doi.org/10.3389/fgene.2015.00041 |
Ejemplares similares
-
Pharmacogenomics and adverse drug reactions in children
por: Rieder, Michael J., et al.
Publicado: (2014) -
Combined approach with therapeutic drug monitoring and pharmacogenomics in renal transplant recipients
por: Manvizhi, S., et al.
Publicado: (2013) -
Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients
por: Marfo, Kwaku, et al.
Publicado: (2010) -
CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients
por: Krall, Paola, et al.
Publicado: (2021) -
Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine
por: Maagdenberg, Hedy, et al.
Publicado: (2016)